Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • emc易倍官网入口Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • emc易倍官网入口Subscribe
    • emc易倍官网入口Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • emc易倍官网入口Working at Ipsen
    • Culture
    • emc易倍官网入口Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • emc易倍官网入口Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • emc易倍官网入口Asia Pacific
    • Europe
    • Middle East & Africa
    • emc易倍官网入口 Brazil
    • emc易倍官网入口 Canada
    • United States
    • Mexico
    • Australia
    • China
    • Singapore
    • emc易倍官网入口 South Korea
    • emc易倍官网入口 Japan
    • emc易倍官网入口 Belgium
    • Ukraine
    • emc易倍官网入口 UK
    • emc易倍官网入口 Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Romania
    • emc易倍官网入口 Hungary
    • emc易倍官网入口 Slovakia
    • Switzerland
    • Austria
    • emc易倍官网入口 UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • emc易倍官网入口Oncology
    • Rare Disease
    • Neuroscience
    • emc易倍官网入口Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • emc易倍官网入口Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • emc易倍官网入口Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • emc易倍官网入口Lay Summaries
      • Find Clinical Trials
    • emc易倍官网入口Pipeline
  • Sustainability
      < Back
    • emc易倍官网入口Sustainability
    • emc易倍官网入口Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • emc易倍官网入口Together for Rare Disease
    • emc易倍官网入口Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Newsroom – Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€161.40

 €3.50 (2.22%)

  • Media Resources
  • Annual Report
  • emc易倍官网入口 Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

emc易倍官网入口 Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-07-19 7:08:58